Skip to main content
Original Research, Chemotherapy, Adverse Events, Oncology Pharmacy Programs/Protocols
Impact of Pharmacist Telephone Follow-Up on Chemotherapy-Induced Nausea and Vomiting
Jenny McCabe, PharmD; Amanda Al-Bahou, PharmD, BCOP; Leann Koontz, PharmD, BCPS, BCOP; Linda Linderbeck, PharmD, BCOP; Michael Verbosky, PharmD, BCPS; Michelle Prieto, PharmD
Read More
Practical Issues in Pharmacy Management, Oncology Pharmacy Programs/Protocols, Clinical Trials
Implementation and Evaluation of a Formal Investigational Drug Service at a Community Cancer Center
Colton Zwart, PharmD, BCOP; Aimee Cloud, PharmD, BCOP; Amanda Kogelman, PharmD, BCOP; Claire Boomershine, PharmD, BCOP
Read More
Original Research, Oncology Pharmacy Programs/Protocols, Oral Therapy
Evaluating Institutional Safety Standards Related to Continuing Oral Antineoplastic Medication Use During Hospitalization
Belinda Li, PharmD, BCOP; Laura Beth Parsons, PharmD, BCOP; Darby Siler, PharmD, BCOP; Rachel Matthews, PharmD, BCOP
Read More
Case Reports, Infections, Transplant, Pediatric Cancer
Isavuconazonium Sulfate Dosing in Pediatric Patients Using Serum Therapeutic Drug Monitoring at a Single Center: A Case Series
Ashley M. Martin, PharmD; Christine E. MacBrayne, PharmD, MSCS, BCIDP; Alyssa Heiden, PharmD; Jason Child, PharmD; Donna J. Curtis, MD, MPH; Andrew S. Haynes, MD
Read More
Case Reports, Sarcoma, Immunotherapy
Complete Pathologic Response to Pembrolizumab in a Patient with Cutaneous Angiosarcoma: Case Report
Michael J. Nathenson, MD, and Jason L. Hornick, MD, PhD
Read More
Original Research, Oncology Pharmacy Programs/Protocols, Oral Therapy
Time to First Palbociclib Prescription Dispense at Mayo Clinic: Comparing a Health-System Specialty Pharmacy with External Specialty Pharmacies
Allison P. Golbach, PharmD; Jodi L. Taraba, PharmD; Matthew D. Smith, PharmD; Kristin C. Mara, MS; Karthik V. Giridhar, MD
Read More
Clinical Trials, Melanoma
Pyrexia Management in Patients with Melanoma Treated with Dabrafenib/Trametinib Combination Therapy
Read More
Case Reports, Lung Cancer, Tyrosine Kinase Inhibitor
Third-Line Tyrosine Kinase Inhibitor Therapy Results in 16-Year Remission in a Patient with Stage IV Non–Small-Cell Lung Cancer
Carrie L. Barnhart, PharmD, BCOP, and David F. Christianson, MD
Read More
Practical Issues in Pharmacy Management
Sterility of Single-Use Vials When Using a Closed-System Transfer Device
Joan Antoni Schoenenberger-Arnaiz, PharmD, PhD; Maria Nevot-Blanc, PharmD; Merce Garcia-Gonzalez, PharmD; Mireia Martinez-Sogues, PharmD; Aida Moroba-Estor; Laura Rumi-Carrera, PharmD; Jason Battle, BS
Read More
FDA Updates
Xalkori Now FDA Approved for the Treatment of ALK-Positive Inflammatory Myofibroblastic Tumor
Read More
Page 50 of 199
Results 491 - 500 of 1986